What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?
4 equities research analysts have issued 1-year price objectives for Supernus Pharmaceuticals' shares. Their forecasts range from $23.00 to $32.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $26.75 in the next year.
When will Supernus Pharmaceuticals announce their earnings?
Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (2/4/2017)
Cantor Fitzgerald analysts commented, "SUPN still trying to reach agreement with generic challengers. Based on a recent conversation with management, we understand that the company will continue to try and reach a settlement with Actavis and Zydus regarding infringement of patents related to Trokendi XR. We believe the judge in the case would prefer the companies reach a settlement vs. advance to a court trial." (1/12/2017)
Who owns Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ranger Investment Management L.P. (2.88%), State Street Corp (2.60%), Dimensional Fund Advisors LP (2.21%), Fiera Capital Corp (2.18%), Russell Investments Group Ltd. (1.71%) and Neumeier Poma Investment Counsel LLC (1.55%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jones W Bryan, M James Barrett, Padmanabh P Bhatt, Scott D Sandell and Stefan KF Schwabe.
Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Neumeier Poma Investment Counsel LLC, Fiera Capital Corp, Oxford Asset Management, Allianz Asset Management AG, Guggenheim Capital LLC, Ranger Investment Management L.P. and Menta Capital LLC. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick and Padmanabh P Bhatt.
Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Axiom International Investors LLC DE, Bogle Investment Management L P DE, Dimensional Fund Advisors LP, State Street Corp, Trexquant Investment LP, Holderness Investments Co. and Tudor Investment Corp Et Al.
How do I buy Supernus Pharmaceuticals stock?
Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Supernus Pharmaceuticals stock cost?
One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $25.30.